12 Best ADR Stocks To Invest In According to Analysts

Page 6 of 11

6. Sanofi (NASDAQ:SNY)

Upside Potential: 32.08%

Sanofi (NASDAQ:SNY) is a French multinational pharmaceutical company focusing on prescription medicines, vaccines, and consumer healthcare products. The company earns revenue by developing and marketing treatments for chronic diseases, rare conditions, and infectious diseases. Sanofi’s (NASDAQ:SNY) growth is propelled by strong demand for its flagship drugs such as Dupixent (for asthma and eczema) and an expanding vaccine portfolio. The company is also investing heavily in R&D to capture opportunities in immunology and oncology.

In Q3, Sanofi (NASDAQ:SNY) reported strong earnings, beating expectations with the company’s revenue increasing 16% year-over-year to $14.09 billion. The company’s Pharma sales increased 13.0% to $8.80 billion, mainly driven by Dupixent and other newly launched medicines. Dupixent sales increased 23.8% year over year to $3.66 billion in the quarter, driven by its sixth indication approval for chronic obstructive pulmonary disease (COPD) in the United States in September. Sanofi (NASDAQ:SNY) vaccine sales increased 25.5% to $3.99 billion, driven by earlier-than-anticipated deliveries of respiratory syncytial virus (RSV), vaccine Beyfortus and flu vaccines.

Sanofi (NASDAQ:SNY) expects to present several Phase 3 readouts, submissions, and regulatory decisions in the next 18 months. The company’s anti-CD38 molecule, Sarclisa, has also been approved in the US for adult patients with newly diagnosed multiple myeloma who are not eligible for transplantation. and shareholders.

Page 6 of 11